Equity Profile

NBIX

Neurocrine Biosciences, Inc.

Health CareBiotechnology$16.5B

Jul29Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Neurocrine Biosciences, Inc. (NBIX) is a biotechnology company focused on developing treatments for neurological and endocrine diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely watch.

Not available

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and increase sales of its products.

Not available

Wall Street expectations, options signals, track record, and call prep available with Pro.

NBIX Q2-2026 Earnings Preview

Context

Company Snapshot

Neurocrine Biosciences, Inc. (NBIX) is a biotechnology company focused on developing treatments for neurological and endocrine diseases. With a market cap of $16 billion, it plays a significant role in the healthcare sector, particularly in addressing unmet medical needs.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+36.15%

Avg Stock Reaction

+2.03%

Last Quarter Recap

In Q1 2026, Neurocrine reported an EPS of $1.94, significantly beating expectations of $1.28, showcasing strong financial performance. However, revenue figures were not disclosed.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are optimistic about Neurocrine's upcoming earnings, especially given its strong track record of beating EPS estimates. However, the lack of revenue guidance raises some uncertainty.

Bull Case

If Neurocrine continues its trend of beating EPS estimates, it could signal robust underlying business performance and lead to positive stock movement.

Bear Case

Conversely, if the company fails to provide clear revenue guidance or if the EPS surprise is not as significant as expected, it may lead to a negative reaction in the stock.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to previous quarters?

Given the company's strong history of beating EPS estimates, this number will be crucial for investor sentiment.

Will there be any guidance on revenue growth for the upcoming quarters?

Clear revenue guidance can provide insights into the company's future performance and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Neurocrine's ability to maintain its earnings momentum, particularly given its recent strong performance.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating strong operational execution.

Options pricing suggests a significant expected move, reflecting investor uncertainty that could lead to a surprise.

The lack of revenue guidance may be seen as a risk, but strong EPS could overshadow this concern.

Key Risk

If EPS comes in below $1.50, it could lead to a reevaluation of the company's growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will either reinforce the company's growth trajectory or raise concerns about its future.

Bull Confirmed If

An EPS of $2.00 or higher would confirm the bull case, indicating strong profitability.

Bear Confirmed If

An EPS below $1.50 would confirm the bear case, suggesting potential issues in the business.

Pre-Earnings Positioning

Options Market

Implied Move

±4.97%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a nearly 5% move in either direction, indicating heightened expectations for volatility around the earnings report.

Options are pricing ±3.8% while NBIX has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

33.4%

Calls (1K)P/C Ratio: 0.16Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Neurocrine beats expectations, history suggests the stock could rise by around 2.03%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see muted movement as investors reassess their outlook.

Miss

A miss on EPS could lead to a decline, with history suggesting a potential drop of around 2.03%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements or new drug approvals.
2Insights into market share changes in key therapeutic areas.
3Management's commentary on competitive pressures in the biotechnology sector.
4Details on cost management strategies and their impact on margins.
5Any indications of future partnerships or collaborations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

Insider activity

PreviewView

Jul

Company Snapshot

Neurocrine Biosciences, Inc. (NBIX) is a biotechnology company focused on developing treatments for neurological and endocrine diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely watch.

Not available

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and increase sales of its products.

Not available

Wall Street expectations, options signals, track record, and call prep available with Pro.

NBIX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+36.15%

Avg Stock Reaction

+2.03%

Last Quarter Recap

In Q1 2026, Neurocrine reported an EPS of $1.94, significantly beating expectations of $1.28, showcasing strong financial performance. However, revenue figures were not disclosed.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are optimistic about Neurocrine's upcoming earnings, especially given its strong track record of beating EPS estimates. However, the lack of revenue guidance raises some uncertainty.

Bull Case

If Neurocrine continues its trend of beating EPS estimates, it could signal robust underlying business performance and lead to positive stock movement.

Bear Case

Conversely, if the company fails to provide clear revenue guidance or if the EPS surprise is not as significant as expected, it may lead to a negative reaction in the stock.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to previous quarters?

Given the company's strong history of beating EPS estimates, this number will be crucial for investor sentiment.

Will there be any guidance on revenue growth for the upcoming quarters?

Clear revenue guidance can provide insights into the company's future performance and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Neurocrine's ability to maintain its earnings momentum, particularly given its recent strong performance.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating strong operational execution.

Options pricing suggests a significant expected move, reflecting investor uncertainty that could lead to a surprise.

The lack of revenue guidance may be seen as a risk, but strong EPS could overshadow this concern.

Key Risk

If EPS comes in below $1.50, it could lead to a reevaluation of the company's growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will either reinforce the company's growth trajectory or raise concerns about its future.

Bull Confirmed If

An EPS of $2.00 or higher would confirm the bull case, indicating strong profitability.

Bear Confirmed If

An EPS below $1.50 would confirm the bear case, suggesting potential issues in the business.

Pre-Earnings Positioning

Options Market

Implied Move

±4.97%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a nearly 5% move in either direction, indicating heightened expectations for volatility around the earnings report.

Options are pricing ±3.8% while NBIX has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

33.4%

Calls (1K)P/C Ratio: 0.16Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Neurocrine beats expectations, history suggests the stock could rise by around 2.03%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see muted movement as investors reassess their outlook.

Miss

A miss on EPS could lead to a decline, with history suggesting a potential drop of around 2.03%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements or new drug approvals.
2Insights into market share changes in key therapeutic areas.
3Management's commentary on competitive pressures in the biotechnology sector.
4Details on cost management strategies and their impact on margins.
5Any indications of future partnerships or collaborations.